We found this gene set strongly enriched in TIS control;bcl2 compared to proliferating mouse lymphomas in vitro (Fig. 6a, first panel), and, likewise, strongly up in treatment-naïve NR Eμ-myc lymphomas in vivo (Fig. 6a, second panel), as well as in newly diagnosed DLBCL samples of two independent cohorts of patients who achieved lasting remissions, when being compared to RP mouse or human relapsed/refractory lymphomas, respectively (Fig. 6a, right panels). This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.